Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the standard first‐line therapy in advanced EGFR‐mutant non‐small cell lung cancer (NSCLC).1, 2. This evidence concerns the gene EGFR and non-small cell lung carcinoma.